TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis C$17.95 -0.18 (-0.99%) (As of 09/6/2024 ET) Add Compare Share Share Today's RangeC$17.39▼C$18.5050-Day RangeC$8.15▼C$18.9952-Week RangeC$4.10▼C$19.69Volume41,888 shsAverage Volume39,807 shsMarket CapitalizationC$459.34 millionP/E Ratio14.83Dividend YieldN/APrice TargetC$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlines Get Cipher Pharmaceuticals alerts: Email Address Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Cipher Pharmaceuticals Stock (TSE:CPH)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPH Stock News HeadlinesAugust 17, 2024 | nz.finance.yahoo.comCipher Pharmaceuticals Inc (PHE.SG)August 15, 2024 | finance.yahoo.comCipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You ThinkSeptember 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.August 12, 2024 | finance.yahoo.comCipher Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 9, 2024 | markets.businessinsider.comCipher Pharmaceuticals earnings preview: what Wall Street is expectingAugust 9, 2024 | finance.yahoo.comCipher Pharmaceuticals Reports Second Quarter 2024 ResultsAugust 6, 2024 | baystreet.caScant Lineup of Stocks at 52-Week HighsAugust 1, 2024 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference CallSeptember 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.July 31, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) 31% gain last week benefited both individual investors who own 53% as well as insidersMay 13, 2024 | finance.yahoo.comCipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50April 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)April 27, 2024 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Friday (CPH)April 3, 2024 | ca.finance.yahoo.comStocks in play: Cipher PharmaceuticalsMarch 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)March 17, 2024 | investing.comEarnings call: Cipher Pharmaceuticals outlines growth and financialsMarch 17, 2024 | seekingalpha.comCipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call TranscriptJanuary 5, 2024 | morningstar.comCipher Pharmaceuticals Inc CPHSee More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$12.00 High Stock Price TargetC$16.00 Low Stock Price TargetC$8.00 Potential Upside/Downside-33.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C$1.21 Trailing P/E Ratio14.83 Forward P/E Ratio17.47 P/E GrowthN/ANet IncomeC$22.60 million Net Margins102.01% Pretax MarginN/A Return on Equity28.43% Return on Assets7.90% Debt Debt-to-Equity Ratio0.33 Current Ratio11.18 Quick Ratio2.67 Sales & Book Value Annual SalesC$22.16 million Price / Sales20.73 Cash FlowC$5.09 per share Price / Cash Flow3.53 Book ValueC$3.68 per share Price / Book4.88Miscellaneous Outstanding Shares25,590,000Free FloatN/AMarket CapC$459.34 million OptionableNot Optionable Beta1.24 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey CompetitorsCronos GroupTSE:CRONHydropothecaryCVE:THCXCanopy GrowthTSE:WEEDKnight TherapeuticsTSE:GUDAurora CannabisTSE:ACBView All Competitors CPH Stock Analysis - Frequently Asked Questions How have CPH shares performed this year? Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of the year. Since then, CPH stock has increased by 224.0% and is now trading at C$17.95. View the best growth stocks for 2024 here. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) issued its quarterly earnings data on Thursday, August, 8th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.01. The firm had revenue of $7.26 million for the quarter, compared to the consensus estimate of $7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a trailing twelve-month return on equity of 28.43%. How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA) and This page (TSE:CPH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.